Fabiana Zappala

Fabiana Zappala

Auto-generated profile, based on publicly available information

Fabiana Zappala

Department of Bioengineering, University of Pennsylvania, 210 S. 33rd Street, 240 Skirkanich Hall, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
NMNicholas G. Minutolo
Nicholas G. Minutolo
PSPrannda Sharma
Prannda Sharma
MPMathilde Poussin
Mathilde Poussin
LSLauren C. Shaw
Lauren C. Shaw
DBDaniel P. Brown
Daniel P. Brown
DPDaniel Powell
Daniel Powell

12 December 2021 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
LMLinghan Mei
Linghan Mei
FZFabiana Zappala
Fabiana Zappala
ATAndrew Tsourkas
Andrew Tsourkas

6 May 2022 in Science Advances
Verified
Journal Article
Open access
FZFabiana Zappala
Fabiana Zappala
EHElizabeth Higbee-Dempsey
Elizabeth Higbee-Dempsey
BJBian Jang
Bian Jang
JMJoann Miller
Joann Miller
Lesan YanLesan Yan
Lesan Yan
BOBurcin Altun Ozdemir
Burcin Altun Ozdemir
Extensive antibody engineering and cloning is typically required to generate new bispecific antibodies. Made-to-order genes, advanced expression systems, and high-efficiency cloning can simplify and accelerate this process, but it still can take months before a functional product is realized. We developed a simple method to site-specifically and covalently attach a T cell–redirecting domain to any off-the-shelf, human immunoglobulin G (IgG) or native IgG isolated from serum. No antibody engineering, cloning, or knowledge of the antibody sequence is required. Bispecific antibodies are generated in just hours. By labeling antibodies isolated from tumor-bearing mice, including two syngeneic models, we generated T cell–redirecting autoantibodies (TRAAbs) that act as an effective therapeutic. TRAAbs preferentially bind tumor tissue over healthy tissue, indicating a previously unexplored therapeutic window. The use of autoantibodies to direct the tumor targeting of bispecific antibodies represents a new paradigm in personalized medicine that eliminates the need to identify tumor biomarkers.